Manning Paul B — SEC Form 4 filings
SEC reporting owner CIK 1494695. 20 Form 4 filings on record with FilingPulse; latest filed 2026-07-01.
Transaction summary — filings shown
Covers all 20 filings on record, filed 2024-06-24 to 2026-07-01. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 10 legs across 7 filings — 31,268,359 shares, $36,067,647 total (shares × price as filed on priced legs).
- Open-market sales (code S, non-derivative): 9 legs across 2 filings — 870,837 shares, $31,739,534 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 22.
- Largest priced transaction: purchase of 2,750,762 shares @ $4.24 ($11,670,108) in Verrica Pharmaceuticals Inc., filed 2025-11-25.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Liquidia Corp (LQDA) | Director | 7 | 1 leg · 337,078 sh · $2,999,994 | 9 legs · 870,837 sh · $31,739,534 | 5 |
| Verrica Pharmaceuticals Inc. (VRCA) | Director, 10% owner | 3 | 4 legs · 27,047,490 sh · $17,505,157 | — | 11 |
| Candel Therapeutics, Inc. (CADL) | Director | 8 | 3 legs · 1,800,458 sh · $10,499,996 | — | 6 |
| Taysha Gene Therapies, Inc. (TSHA) | 10% owner | 2 | 2 legs · 2,083,333 sh · $5,062,499 | — | — |
Form 4 filings — Manning Paul B
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-01 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 2,199 (derivative) @ $8.64 | EDGAR |
| 2026-06-24 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Liquidia Corp (LQDA) | Grant/award (A): 5,882 @ $0 | EDGAR |
| 2026-06-08 | 4 | Liquidia Corp (LQDA) | Sale (S): 11,513 @ $63.13 · Sale (S): 88,487 @ $64.28 · Sale (S): 19,125 @ $62.62 · Sale (S): 68,265 @ $63.83 · Sale (S): 12,610 @ $64.42 | EDGAR |
| 2026-04-02 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 4,618 (derivative) @ $4.11 | EDGAR |
| 2026-02-26 | 4 | Candel Therapeutics, Inc. (CADL) | Purchase (P): 550,458 @ $5.45 | EDGAR |
| 2026-02-12 | 4 | Liquidia Corp (LQDA) | Other (J): 55,116 @ $42.63 · Other (J): 55,116 @ $42.63 | EDGAR |
| 2025-11-25 | 4 | Verrica Pharmaceuticals Inc. (VRCA) | Purchase (P): 1,375,380 @ $4.24 · Purchase (P): 2,750,762 @ $4.24 · Purchase (P): 343,845 (derivative) · Purchase (P): 687,690 (derivative) | EDGAR |
| 2025-09-02 | 4 | Liquidia Corp (LQDA) | Sale (S): 154,337 @ $27.94 · Sale (S): 188,232 @ $27.62 · Sale (S): 254,038 @ $28.67 · Sale (S): 74,230 @ $29.14 | EDGAR |
| 2025-06-26 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 1,070,663 @ $4.67 | EDGAR |
| 2025-06-20 | 4 | Liquidia Corp (LQDA) | Grant/award (A): 18,396 @ $0 | EDGAR |
| 2025-06-18 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 14,240 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Taysha Gene Therapies, Inc. (TSHA) | Purchase (P): 750,000 @ $2.75 | EDGAR |
| 2024-12-18 | 4 | Candel Therapeutics, Inc. (CADL) | Purchase (P): 500,000 @ $6 · Purchase (P): 750,000 @ $6 | EDGAR |
| 2024-11-26 | 4 | Verrica Pharmaceuticals Inc. (VRCA) | Purchase (P): 18,426,966 · Purchase (P): 4,494,382 · Gift (G): 450,000 @ $0 · Purchase (P): 9,213,483 (derivative) · Purchase (P): 9,213,483 (derivative) · Purchase (P): 2,247,191 (derivative) · +1 more | EDGAR |
| 2024-09-23 | 4 | Verrica Pharmaceuticals Inc. (VRCA) | Gift (G): 2,675,611.25 @ $0 · Gift (G): 891,870.41 @ $0 · Gift (G): 891,870.42 @ $0 · Gift (G): 891,870.42 @ $0 | EDGAR |
| 2024-09-16 | 4 | Liquidia Corp (LQDA) | Purchase (P): 337,078 @ $8.90 | EDGAR |
| 2024-07-01 | 4 | Taysha Gene Therapies, Inc. (TSHA) | Purchase (P): 1,333,333 @ $2.25 | EDGAR |
| 2024-06-27 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 14,240 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Liquidia Corp (LQDA) | Grant/award (A): 20,359 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1494695 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →